| abstract |
The treatment of diseases in which insulin resistance is the basis of pathophysiological mechanisms and the treatment of hypertension with better efficacy, potency and low toxicity. The present invention relates to 5- [4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl] methoxy] benzyl] thiazolidine-2,4-dione having the formula (I) It relates to a novel crystalline form of the potassium salt. The present invention also relates to pharmaceutical compositions comprising this novel crystalline form and a pharmaceutically acceptable carrier. The novel crystalline form of the present invention is a 5- [4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl] methoxy] benzyl] thiazolidine-, which has been known as an antidiabetic agent. More active than 2,4-dione potassium salt. [Selection figure] None |